The US Food and Drug Administration approved giredestrant, branded Wilserdly, with everolimus on November 16, 2026, for a defined group of adults with ESR1-mutated advanced breast cancer. The decision also authorizes a companion diagnostic, making the relationship between molecular testing, trial evidence and the approved population central to how university research teams and regulatory offices describe the result.
FDA authorizes a biomarker-selected combination
The FDA approval notice identifies giredestrant as an oral estrogen receptor antagonist from Genentech. The indication covers adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, with the mutation detected by an FDA-authorized test.
The prior-treatment condition is part of that indication: disease must have recurred during or after completion of endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting. The reference to previous adjuvant therapy describes treatment history within an advanced-cancer indication. It does not establish an approval to use this combination as adjuvant treatment.
Alongside the medicine decision, FDA authorized FoundationOne Liquid CDx as a companion diagnostic for identifying breast cancers with ESR1 mutations for this combination. For research communications, that creates two linked regulatory facts to record: the authorized drug combination and the assay authorization supporting molecular selection.
What evERA established in the ESR1-mutated population
FDA evaluated efficacy in evERA Breast Cancer, registered as NCT05306340. The randomized, open-label, multicenter trial enrolled 373 adults with ER-positive, HER2-negative locally advanced or metastatic disease. Of those participants, 207 had tumors with ESR1 mutations. The total trial enrollment and the biomarker-defined population therefore represent different denominators.
Participants were assigned to giredestrant or physician-selected endocrine therapy; both groups also received everolimus. The control endocrine options were exemestane, fulvestrant or tamoxifen. The primary outcome was investigator-assessed progression-free survival using RECIST version 1.1. Overall survival and objective response rate were additional outcomes, according to FDA.
The regulator reported the following results for the ESR1-mutated population:
| Trial outcome | Giredestrant plus everolimus | Control endocrine therapy plus everolimus |
|---|---|---|
| Median progression-free survival | 10 months | 5.5 months |
| 95% confidence interval for median progression-free survival | 8.1–12.9 months | 3.8–5.6 months |
| Objective response rate | 27% | 14% |
The progression-free survival hazard ratio was 0.38, with a 95% confidence interval of 0.27–0.54 and a p value below 0.0001. This is a comparison of event hazards over follow-up, not a percentage of participants helped. CASRAI’s guide to interpreting a hazard ratio explains that distinction. The reported medians are trial outcomes, not predictions of an individual’s experience.
FDA described overall survival data as immature at the progression-free survival analysis. The announcement consequently supports a progression-free survival finding; it does not establish a survival benefit. Keeping the endpoint and analysis population attached to each number is essential when moving results into institutional summaries, presentations or evidence reviews.
Independent coverage emphasizes resistance and molecular selection
In his November 16 STAT report, Andrew Joseph described the approval as an important regulatory decision for Roche and placed the ESR1 mutation in the context of resistance to standard endocrine treatments. He also identified giredestrant as a selective estrogen receptor degrader, or SERD. That coverage connects the regulatory event to the scientific problem of endocrine resistance.
OncLive’s November 16 report by Ashling Wahner highlighted the companion diagnostic and the ESR1-mutated subgroup supporting the decision. Its account distinguishes the full evERA population from the subgroup relevant to this authorization. For readers of trial coverage, that distinction matters: enrollment in a broader study does not make every participant’s disease characteristics part of the final approved indication.
Research offices can connect assay records to endpoint reporting
FDA says circulating tumor DNA was assessed centrally with FoundationOne Liquid CDx to determine ESR1 mutation status, with assessment limited to specified mutations in the receptor’s ligand-binding domain. An operational implication for university translational research teams is that a generic entry reading “ESR1 positive” omits information about how the trial defined its molecular population.
For evidence abstraction, the useful record connects assay identity, mutation definition, analysis population, comparator and endpoint. This is an editorial implication of the FDA account, rather than a new reporting mandate. Teams maintaining a clinical trial management system or preparing institutional research briefings can use those distinctions to preserve the meaning of the source result.
The same separation applies to protocol and manuscript discussions: the trial’s design, the population analyzed and the regulator’s indication answer different questions. CASRAI’s background on clinical trial endpoints and analysis planning provides context for reading those elements together.
International review and assessment documentation
The application was reviewed through Project Orbis, the FDA Oncology Center of Excellence framework for concurrent submission and review across international regulators. For this application, FDA collaborated with Health Canada and Israel’s Ministry of Health. FDA’s Orbis information explicitly distinguishes US approval dates from partner-agency decisions; participation does not establish authorization in another jurisdiction.
FDA also says this review used its Assessment Aid. The voluntary document separates objective data, the applicant’s interpretation and FDA’s assessment. Its instructions call for references to study reports and relevant datasets, identification of datasets behind tables, and avoidance of promotional language. For research offices contributing evidence to sponsor submissions, this is a concrete example of how data provenance and ownership of interpretation enter regulatory documentation.
What follows the US decision
FDA said the November 16 approval came four weeks before its goal date and that full prescribing information would be posted on Drugs@FDA. That document is the announced next regulatory reference for the US authorization. The notice also says applications at partner agencies may still be in submission or under review.
For international research collaborations, the practical implication is to track each jurisdiction’s decision separately. The dated US approval, the named Orbis partners and any subsequent national authorization are distinct entries in a regulatory record. FDA’s announcement provides the US decision and collaboration details, without assigning partner-agency approval dates.
Sources
- FDA: FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. November 16, 2026; checked 2026-11-17.
- STAT: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche. Andrew Joseph, November 16, 2026; checked 2026-11-17. Publicly readable opening.
- OncLive: FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer. Ashling Wahner, November 16, 2026; checked 2026-11-17.
- FDA: Project Orbis. Updated October 29, 2026; checked 2026-11-17.
- FDA: Assessment Aid. Updated November 18, 2024; checked 2026-11-17.







